This is not the most recent version of the article. View current version (16 FEB 2011)

Intervention Review

Creatine for treating muscle disorders

  1. Rudolf A Kley1,*,
  2. Matthias Vorgerd1,
  3. Mark A Tarnopolsky2

Editorial Group: Cochrane Neuromuscular Disease Group

Published Online: 8 JUL 2009

Assessed as up-to-date: 2 SEP 2006

DOI: 10.1002/14651858.CD004760.pub2

Database Title

Additional Information

How to Cite

Kley RA, Vorgerd M, Tarnopolsky MA. Creatine for treating muscle disorders. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD004760. DOI: 10.1002/14651858.CD004760.pub2.

Author Information

  1. 1

    Kliniken Bergmannsheil, Ruhr University Bochum, Department of Neurology, Bochum, Germany

  2. 2

    McMaster University, Department of Neurology and Rehabilitation, Hamilton, Ontario, Canada

*Rudolf A Kley, Department of Neurology, Kliniken Bergmannsheil, Ruhr University Bochum, Buerkle-de-la-Camp-Platz 1, Bochum, 44789, Germany. rudolf.a.kley@ruhr-uni-bochum.de.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 8 JUL 2009

SEARCH

ARTICLE TOOLS

This is not the most recent version of the article.View current version (16 Feb 2011)

View Full Article (HTML) Summary (57K)Standard (308K)Full (372K)

  1. Current Version

    Creatine for treating muscle disorders

    Rudolf A Kley, Mark A Tarnopolsky and Matthias Vorgerd

    Article first published online: 16 FEB 2011 | DOI: 10.1002/14651858.CD004760.pub3

Previous versions of this article and their online publication dates

  1. Version 2

    Creatine for treating muscle disorders

    Rudolf A Kley, Matthias Vorgerd and Mark A Tarnopolsky

    Article first published online: 8 JUL 2009 | DOI: 10.1002/14651858.CD004760.pub2

  2. Version 1

    Creatine for treating muscle disorders

    RA Kley, M Vorgerd and MA Tarnopolsky

    Article first published online: 18 OCT 2006 | DOI: 10.1002/14651858.CD004760

View Full Article (HTML) Summary (57K)Standard (308K)Full (372K)